Product image of Mestinon (Pyridostigmine Bromide) supplied by GNH India

Mestinon

Active Ingredient:
Pyridostigmine Bromide
Origin:
EU

Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is employed to improve neuromuscular transmission in myasthenia gravis and may be used in postoperative ileus and orthostatic hypotension management.

GNH India supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mestinon is an acetylcholinesterase inhibitor used in disorders where enhanced neuromuscular transmission is required.

  • Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction.
  • Postoperative ileus: stimulates intestinal motility to aid recovery after surgery.
  • Orthostatic hypotension (off‑label): supports blood pressure regulation by augmenting autonomic cholinergic activity.

How It Works

  • Pyridostigmine bromide reversibly inhibits acetylcholinesterase, the enzyme responsible for breaking down acetylcholine at synaptic clefts. By slowing acetylcholine degradation, it raises the concentration of this neurotransmitter at neuromuscular junctions and autonomic synapses, thereby enhancing cholinergic transmission and improving muscle contraction and autonomic tone.

Side Effects

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: increased bowel movements.
  • Abdominal cramps: discomfort in the stomach area.
  • Excessive salivation: increased oral secretions.
  • Muscle cramps: involuntary tightening of skeletal muscles.
  • Sweating: heightened perspiration.

Serious or Rare Side Effects

  • Cholinergic crisis: severe muscle weakness and respiratory compromise.
  • Bradycardia: markedly slow heart rate.
  • Bronchospasm: narrowing of airways causing breathing difficulty.
  • Seizures: uncontrolled electrical activity in the brain.
  • Severe allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Prolonged QT interval: potential cardiac rhythm disturbance.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Renal impairment: adjust dose because the drug is primarily excreted unchanged.
  • History of asthma or COPD: monitor for bronchospasm.
  • Concomitant anticholinesterases: avoid additive cholinergic effects.
  • Cardiovascular disease: watch for bradycardia or arrhythmias.
  • Pregnancy and lactation: safety data are limited; use only if clearly needed.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Pyridostigmine bromide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Other anticholinesterases (e.g., neostigmine, physostigmine): risk of cholinergic overload.
  • Beta‑adrenergic blockers: may mask tachycardia caused by cholinergic excess.
  • Magnesium sulfate: potentiates neuromuscular blockade.

Moderate Interactions (Monitor Closely)

  • Aminoglycoside antibiotics: may enhance neuromuscular weakness.
  • Beta‑2 agonists: could reduce the drug’s effectiveness on muscle strength.
  • Loop diuretics: may increase renal clearance, requiring dose adjustment.

Frequently Asked Questions

Mestinon (pyridostigmine bromide) is prescribed primarily for myasthenia gravis, a disorder that causes muscle weakness. It is also used to stimulate intestinal motility after surgery (postoperative ileus) and, off‑label, to help manage orthostatic hypotension by supporting autonomic blood pressure control.

Pyridostigmine bromide reversibly blocks acetylcholinesterase, the enzyme that breaks down acetylcholine. By inhibiting this enzyme, the drug raises acetylcholine levels at neuromuscular and autonomic junctions, enhancing nerve‑to‑muscle signaling and improving muscle strength and autonomic function.

The exact dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. Dosage adjustments are made to achieve optimal clinical benefit while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mestinon is an oral anticholinesterase that directly increases acetylcholine at the neuromuscular junction, offering rapid symptomatic relief. Other options include immunosuppressants, corticosteroids, and biologics such as eculizumab, which target the underlying immune response. Choice of therapy depends on disease severity, patient tolerance, and long‑term management goals.

Mestinon should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mestinon is taken orally, usually in tablet form, with or without food as directed by the prescriber. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as profound bradycardia, bronchospasm, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these symptoms develop.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any component of the formulation, and it should be avoided in individuals with severe asthma or chronic obstructive pulmonary disease who are prone to bronchospasm, unless closely monitored by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pyridostigmine Bromide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT